Investor Relations

Home > Investor Relations > IR Library > Statements of Income and Loss (consolidated)

Statements of Income and Loss (consolidated)

(million yen) 
  FY2016
(2016/4/1-2017/3/31)
FY2017
(2017/4/1-2018/3/31)
Net sales 84,949 93,430
COGS 45,902 50,379
Gross Profit 39,046 43,050
SGA 32,176 31,407
Operating income 6,869 11,643
Non-operating income 1,307 1,632
Interest earned 29 58
Dividends earned 4 4
Subsidy income 99 590
Currency gain 551 603
Other non-operating income 623 374
Non-operating expenses 760 1,557
Interest paid 164 158
Loss on revaluation of currency swaps 502 1,334
Other non-operating expenses 92 65
Ordinary income 7,417 11,717
Extraordinary gain 1 0
Gain on sale of fixed assets 1 0
Extraordinary loss 180 1,883
Loss on disposal of fixed assets 177 83
Impairment loss - 1,800
Other extraordinary loss 3 -
Net income before income taxes 7,237 9,833
Income taxes 1,741 3,411
Income taxes-deferred 79 73
Total income taxes 1,661 3,338
Income before minority interests 5,576 6,495
Profit attributable to owners of parent 5,576 6,495

Home > Investor Relations > IR Library > Statements of Income and Loss (consolidated)
© Copyright TOWA PHARMACEUTICAL CO.,LTD. All Rights Reserved.